{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:11:49Z","timestamp":1794438709326,"version":"4.9.1"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T00:00:00Z","timestamp":1527120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CON-105529"],"award-info":[{"award-number":["CON-105529"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","award":["HLTC3968FL-2010-2235"],"award-info":[{"award-number":["HLTC3968FL-2010-2235"]}],"id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12,3]]},"DOI":"10.1093\/jcag\/gwy018","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T15:10:31Z","timestamp":1522336231000},"page":"159-173","source":"Crossref","is-referenced-by-count":36,"title":["Budesonide for the Induction and Maintenance of Remission in Crohn\u2019s Disease: Systematic Review and Meta-Analysis for the Cochrane Collaboration"],"prefix":"10.1093","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-8426","authenticated-orcid":false,"given":"M Ellen","family":"Kuenzig","sequence":"first","affiliation":[{"name":"CHEO Inflammatory Bowel Disease Centre, Division of Gastroenterology Hepatology & Nutrition, Children\u2019s Hospital of Eastern Ontario, Ontario, Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Rezaie","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilaad G","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Calgary, Calgary, Canada"},{"name":"Department of Community Health Sciences, University of Calgary, Calgary, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony R","family":"Otley","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, IWK Health Centre, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Hillary","family":"Steinhart","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Mount Sinai Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology & Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8855-3598","authenticated-orcid":false,"given":"Eric I","family":"Benchimol","sequence":"additional","affiliation":[{"name":"CHEO Inflammatory Bowel Disease Centre, Division of Gastroenterology Hepatology & Nutrition, Children\u2019s Hospital of Eastern Ontario, Ontario, Ottawa, Canada"},{"name":"Department of Pediatrics and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1551-9054","authenticated-orcid":false,"given":"Cynthia H","family":"Seow","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Calgary, Calgary, Canada"},{"name":"Department of Community Health Sciences, University of Calgary, Calgary, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,5,24]]},"reference":[{"issue":"9573","key":"2019052212495956800_CIT0001","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","article-title":"Inflammatory bowel disease: Clinical aspects and established and evolving therapies","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"issue":"9","key":"2019052212495956800_CIT0002","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1542\/pir.26-9-314","article-title":"Inflammatory bowel disease","volume":"26","author":"Hyams","year":"2005","journal-title":"Pediatr Rev"},{"issue":"6","key":"2019052212495956800_CIT0003","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/j.1572-0241.2008.01836.x","article-title":"Immunosuppressant medications and mortality in inflammatory bowel disease","volume":"103","author":"Lewis","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2019052212495956800_CIT0004","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.addr.2004.08.009","article-title":"Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide","volume":"57","author":"Fedorak","year":"2005","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"8","key":"2019052212495956800_CIT0005","first-page":"CD002913","article-title":"Budesonide for maintenance of remission in Crohn\u2019s disease","author":"Kuenzig","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2019052212495956800_CIT0006","first-page":"CD000296","article-title":"Budesonide for induction of remission in Crohn\u2019s disease","author":"Rezaie","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"2019052212495956800_CIT0007","first-page":"CD000296","article-title":"Crohn\u2019s disease: Budesonide for induction of remission","author":"Modigliani","year":"1996","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2019052212495956800_CIT0008","first-page":"CD000296","article-title":"Budesonide for induction of remission in Crohn\u2019s disease","author":"Otley","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"2019052212495956800_CIT0009","first-page":"CD000296","article-title":"Budesonide for induction of remission in Crohn\u2019s disease (Review)","author":"Seow","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2019052212495956800_CIT0010","first-page":"CD002913","article-title":"Budesonide for maintenance of remission in Crohn\u2019s disease (Review)","author":"Benchimol","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2019052212495956800_CIT0011","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Annals of Internal Medicine"},{"key":"2019052212495956800_CIT0012","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"issue":"7650","key":"2019052212495956800_CIT0013","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"3","key":"2019052212495956800_CIT0014","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"7414","key":"2019052212495956800_CIT0015","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"5","key":"2019052212495956800_CIT0016","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1365-2036.1998.00321.x","article-title":"Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn\u2019s disease","volume":"12","author":"D\u2019Haens","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2019052212495956800_CIT0017","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/gut.48.2.186","article-title":"Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn\u2019s disease","volume":"48","author":"Cortot","year":"2001","journal-title":"Gut"},{"issue":"9","key":"2019052212495956800_CIT0018","first-page":"339","article-title":"Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn\u2019s disease in remission","volume":"65","author":"de Jong","year":"2007","journal-title":"Neth J Med"},{"issue":"2","key":"2019052212495956800_CIT0019","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00005176-200302000-00017","article-title":"A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease","volume":"36","author":"Levine","year":"2003","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"2019052212495956800_CIT0020","first-page":"PI29","article-title":"Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn\u2019s disease: An open-label, budesonide-controlled, randomized study","volume":"12","author":"Tursi","year":"2006","journal-title":"Med Sci Monit"},{"issue":"2","key":"2019052212495956800_CIT0021","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2036.1995.tb00367.x","article-title":"Budesonide and prednisolone suppress peripheral blood natural killer cells in Crohn\u2019s disease","volume":"9","author":"Van Ierssel","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"2019052212495956800_CIT0022","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ibd.20777","article-title":"Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn\u02bcs disease","volume":"15","author":"Mantzaris","year":"2009","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"2019052212495956800_CIT0023","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/cgh.2003.50015","article-title":"Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn\u2019s disease","volume":"1","author":"Mantzaris","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2019052212495956800_CIT0024","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1542-3565(04)00662-7","article-title":"Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn\u2019s disease","volume":"3","author":"Schoon","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"2019052212495956800_CIT0025","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1046\/j.1365-2036.2000.00867.x","article-title":"Budesonide in the treatment of Crohn\u2019s disease: A meta-analysis","volume":"14","author":"Papi","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"2019052212495956800_CIT0026","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1046\/j.1365-2036.2002.01289.x","article-title":"Systematic review: The effectiveness of budesonide therapy for Crohn\u2019s disease","volume":"16","author":"Kane","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"2019052212495956800_CIT0027","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/ajg.2011.70","article-title":"Glucocorticosteroid therapy in inflammatory bowel disease: Systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2019052212495956800_CIT0028","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1056\/NEJM199808063390603","article-title":"A comparison of budesonide and mesalamine for active Crohn\u2019s disease","volume":"339","author":"Thomsen","year":"1998","journal-title":"N Engl J Med"},{"issue":"2","key":"2019052212495956800_CIT0029","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1053\/j.gastro.2010.11.004","article-title":"Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn\u2019s disease","volume":"140","author":"Tromm","year":"2011","journal-title":"Gastroenterology"},{"issue":"4","key":"2019052212495956800_CIT0030","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/ibd.21813","article-title":"Setting a high threshold for noninferiority: Mesalamine and budesonide in Crohn\u02bcs disease","volume":"18","author":"Levesque","year":"2012","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"2019052212495956800_CIT0031","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/apt.13190","article-title":"Systematic review with network meta-analysis: Comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn\u2019s disease","volume":"41","author":"Moja","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"2019052212495956800_CIT0032","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MIB.0000000000001023","article-title":"Comparative effectiveness of mesalamine, sulfasalazine, corticosteroids, and budesonide for the induction of remission in Crohn\u2019s disease: A Bayesian network meta-analysis","volume":"23","author":"Coward","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2019052212495956800_CIT0033","first-page":"CD008870","article-title":"Aminosalicylates for induction of remission or response in Crohn\u2019s disease","volume":"7","author":"Lim","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2019052212495956800_CIT0034","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1572-0241.2002.05609.x","article-title":"Bone mineral density in Crohn\u2019s disease: A longitudinal study of budesonide, prednisone, and nonsteroid therapy","volume":"97","author":"Cino","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"2019052212495956800_CIT0035","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0016-5085(98)70254-9","article-title":"Budesonide versus prednisone in the treatment of active Crohn\u2019s disease","volume":"115","author":"Bar-Meir","year":"1998","journal-title":"Gastroenterology"},{"issue":"2","key":"2019052212495956800_CIT0036","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/gut.41.2.209","article-title":"Oral budesonide is as effective as oral prednisolone in active Crohn\u2019s disease","volume":"41","author":"Campieri","year":"1997","journal-title":"Gut"},{"issue":"1","key":"2019052212495956800_CIT0037","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00042737-200401000-00008","article-title":"Budesonide versus prednisolone for the treatment of active Crohn\u2019s disease in children","volume":"16","author":"Escher","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"13","key":"2019052212495956800_CIT0038","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM199409293311303","article-title":"Oral budesonide for active Crohn\u2019s disease. Canadian Inflammatory Bowel Disease Study Group","volume":"331","author":"Greenberg","year":"1994","journal-title":"N Engl J Med"},{"issue":"9","key":"2019052212495956800_CIT0039","first-page":"905","article-title":"Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn\u2019s disease. German\/Austrian Budesonide Study Group","volume":"8","author":"Gross","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"13","key":"2019052212495956800_CIT0040","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJM199409293311304","article-title":"A comparison of budesonide with prednisolone for active Crohn\u2019s disease","volume":"331","author":"Rutgeerts","year":"1994","journal-title":"N Engl J Med"},{"issue":"3","key":"2019052212495956800_CIT0041","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.crohns.2012.06.006","article-title":"Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn\u2019s disease: A multicentre, double-blind, randomized, parallel-group Phase II study","volume":"7","author":"Suzuki","year":"2013","journal-title":"J Crohn\u2019s Colitis"},{"issue":"7","key":"2019052212495956800_CIT0042","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1111\/j.1572-0241.2002.05835.x","article-title":"Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn\u2019s disease: A randomized placebo-controlled study in the United States","volume":"97","author":"Tremaine","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2019052212495956800_CIT0043","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00042737-199903000-00011","article-title":"Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn\u2019s disease: A multicentre randomized placebo-controlled trial. German Budesonide Study Group","volume":"11","author":"Ewe","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"2019052212495956800_CIT0044","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2036.1998.00285.x","article-title":"Oral budesonide as maintenance therapy in Crohn\u2019s disease\u2014results of a 12-month study","volume":"12","author":"Ferguson","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2019052212495956800_CIT0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/gast.1996.v110.pm8536887","article-title":"Oral budesonide as maintenance treatment for Crohn\u2019s disease: A placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group","volume":"110","author":"Greenberg","year":"1996","journal-title":"Gastroenterology"},{"issue":"4","key":"2019052212495956800_CIT0046","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/gut.42.4.493","article-title":"Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn\u2019s disease","volume":"42","author":"Gross","year":"1998","journal-title":"Gut"},{"issue":"4","key":"2019052212495956800_CIT0047","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2036.2005.02338.x","article-title":"Budesonide as maintenance treatment in Crohn\u2019s disease: A placebo-controlled trial","volume":"21","author":"Hanauer","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2019052212495956800_CIT0048","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0016-5085(99)70125-3","article-title":"Oral budesonide for prevention of postsurgical recurrence in Crohn\u2019s disease","volume":"116","author":"Hellers","year":"1999","journal-title":"Gastroenterology"},{"issue":"1","key":"2019052212495956800_CIT0049","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/gut.39.1.82","article-title":"Budesonide prolongs time to relapse in ileal and ileocaecal Crohn\u2019s disease: A placebo controlled one year study","volume":"39","author":"Lofberg","year":"1996","journal-title":"Gut"}],"container-title":["Journal of the Canadian Association of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcag\/article-pdf\/1\/4\/159\/28695663\/gwy018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T13:27:46Z","timestamp":1558531666000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcag\/article\/1\/4\/159\/5002120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,24]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,5,24]]},"published-print":{"date-parts":[[2018,12,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jcag\/gwy018","relation":{},"ISSN":["2515-2084","2515-2092"],"issn-type":[{"value":"2515-2084","type":"print"},{"value":"2515-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,12]]},"published":{"date-parts":[[2018,5,24]]}}}